Logo for Passage Bio Inc

Passage Bio Investor Relations Material

Latest events

Logo for Passage Bio Inc

Study Result

Passage Bio
Logo for Passage Bio

Q3 2023

13 Nov, 2023
Logo for Passage Bio

Study Result

7 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The Company's lead products in clinical development are TB-403, a novel oligonucleotide modulator of thromboxane receptors (TXRs) and P7C3, a small molecule oral GPCR modulator that targets the vasoactive intestinal peptide (VIP). The company has a bold vision to fulfill the promise of gene therapy by delivering medicines that provide a cure for previously incurable diseases